Form 4: Decheng Capital Reduces Stake in BeyondSpring Inc.

Decheng Capital, a 10% owner and director, reported selling over 131,000 BeyondSpring Inc. ordinary shares in mid-October 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., identified as a 10% owner and director of BeyondSpring Inc. (BYSI), reported sales of ordinary shares.
• On October 16, 2025, 85,798 ordinary shares were sold at a weighted average price of $1.72 per share, with transaction prices ranging from $1.62 to $1.795.
• On October 17, 2025, an additional 45,513 ordinary shares were sold at a weighted average price of $1.76 per share, with transaction prices ranging from $1.73 to $1.80.
• These transactions were executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following these sales, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,518,893 ordinary shares.
• Other related Decheng Capital entities, including Decheng Capital China Life Sciences USD Fund II, L.P. and Decheng Capital Global Healthcare Fund (Master), LP, continue to hold 1,617,409 and 891,734 ordinary shares, respectively.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a 10% owner and director, even though the transactions were pre-planned under Rule 10b5-1. This reduction in stake by a knowledgeable party can signal reduced confidence or a strategic divestment.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, indicating the transactions were pre-scheduled and not necessarily based on new, non-public information.

Negatives

• A significant shareholder and director, Decheng Capital, reduced its stake in BeyondSpring Inc. by a total of 131,311 ordinary shares.
• Insider selling, even under a 10b5-1 plan, can be perceived negatively by the market as it indicates a reduction in exposure by a knowledgeable party.

Risks

• Potential negative market perception due to insider selling by a significant shareholder and director.
• The reduction in ownership by a major institutional investor could signal a lack of conviction or a strategic portfolio rebalancing.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing, which primarily reports past insider transactions.

Industry Context

This Form 4 filing reports an insider transaction and does not provide broader industry context. However, insider selling by a major institutional investor in a biotechnology company can sometimes be interpreted by the market as a signal regarding future prospects or a strategic shift in the investor's portfolio allocation within the life sciences sector.

Comparison to Industry Standards

• This filing reports insider trading activity and does not contain information suitable for comparison to industry-specific operational or financial benchmarks. It is a disclosure of ownership changes by a significant shareholder.

Management Changes

Related Party Transactions

• The reported sales of ordinary shares by Decheng Capital entities are considered related party transactions, as Decheng Capital is a 10% owner and has a director relationship with BeyondSpring Inc.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• Company Management: The reduction in a major investor's stake could influence strategic decisions or investor relations efforts.

Next Steps

• No specific future actions or milestones were mentioned in this Form 4 filing beyond the reporting obligations for insider transactions.

Key Dates

Recommendation

The significant insider selling by Decheng Capital, a 10% owner and director, suggests a lack of conviction or a strategic divestment from BeyondSpring Inc. While the sales were conducted under a 10b5-1 plan, the sheer volume of shares sold (131,311) by a knowledgeable party is a strong negative signal. This action could lead to negative market sentiment and potential downward pressure on the stock price, making a 'sell' recommendation prudent for investors seeking to mitigate risk or reallocate capital.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, Insider Selling, Form 4, Share Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals, Investment Fund